Michael Lahn

7PUBLICATIONS
77CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Infectious agentsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 28, 2026
Application of sample stabilization and mass cytometry in global oncology trials: lessons from regulatory T cell monitoring.

|Oct 09, 2026
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.

|Oct 08, 2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.

|Sep 22, 2023
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.

Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini

|Sep 05, 2023
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Lars van der Veen, Michael Schmitt, Marcel A Deken

|Apr 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoë Johnson, Chiara Tarantelli, Elisa Civanelli

Pageof 2

Frequent Collaborators

5 joint publications

Giusy Di Conza

3 joint publications

Lars van der Veen

2 joint publications

Armando Santoro

2 joint publications

Tracey Hammett